Known targets — ChEMBL curated mechanism
APH1AAPH1BNCSTNPSEN1PSEN2PSENEN
The experimentally established mechanism targets of Semagacestat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 known ✓ | P49768 | 19/20 | 1.00 |
| ▸ | PSEN2 known ✓ | P49810 | 19/20 | 1.00 |
| ▸ | APH1B known ✓ | Q8WW43 | 19/20 | 1.00 |
| ▸ | NCSTN known ✓ | Q92542 | 19/20 | 1.00 |
| ▸ | APH1A known ✓ | Q96BI3 | 19/20 | 1.00 |
| ▸ | PSENEN known ✓ | Q9NZ42 | 19/20 | 1.00 |
| ▸ | XIAP | P98170 | 1/20 | 0.69 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Semagacestat SCHEMBL417581 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Semagacestat SCHEMBL12050112 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Semagacestat SCHEMBL13387771 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Semagacestat SCHEMBL14876852 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Semagacestat SCHEMBL30579757 | 0.99 | PSEN1 (0.98) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Semagacestat SCHEMBL1812166 | 0.99 | PSEN1 (0.98) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL21577575 | 0.90 | PSEN1 (0.81) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL18301563 | 0.86 | PSEN1 (0.76) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7849704 | 0.85 | XIAP (0.77) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4537099 | 0.85 | PSEN1 (0.74) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 592 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12599587-B2 | Chlorinated tetralin compounds and pharmaceutical compositions | SPRINGWORKS THERAPEUTICS, INC. (US) | 2026-04-14 | — | — | US | claimed |
| EP-4720261-A1 | NOVEL CULTURE CONDITIONS FOR CLONAL EXPANSION OF NEPHRON PROGENITOR CELLS, GENERATION OF NEPHRON ORGANOIDS, AND RAPID AND SCALABLE MODELING OF POLYCYSTIC KIDNEY DISEASE | University of Southern California (US) | 2026-04-08 | — | — | EP | claimed |
| US-20260060960-A1 | GAMMA-SECRETASE INHIBITORS FOR USE IN THE TREATMENT OF INHERITED EPIDERMOLYSIS BULLOSA | OSPEDALE PEDIATRICO BAMBINO GESU (IT) | 2026-03-05 | — | — | US | claimed |
| US-12559559-B2 | Targeting Galectin-9 as a therapeutic strategy for T-cell exhaustion in T-cell acute lymphoblastic leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-02-24 | — | — | US | claimed |
| US-20260034099-A1 | CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS | SPRINGWORKS THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | claimed |
| US-20260027084-A1 | TREATMENT OF MULTIPLE MYELOMA | SPRINGWORKS THERAPEUTICS INC (US) | 2026-01-29 | — | — | US | claimed |
| US-20250340837-A1 | CELLS | UNIVERSITY OF GENEVA (CH) | 2025-11-06 | — | — | US | claimed |
| US-20250304916-A1 | METHODS AND COMPOSITIONS FOR GENERATING VASCULAR LEPTOMENINGEAL CELLS | TRAILHEAD BIOSYSTEMS INC (US) | 2025-10-02 | — | — | US | claimed |
| US-20250281638-A1 | Compositions and Methods for Activating Natural Killer Cells | CHIMERA BIOENGINEERING, INC. (US) | 2025-09-11 | — | — | US | claimed |
| EP-4612298-A1 | BCMA VH-ONLY CARS | Dana-Farber Cancer Institute, Inc. (US) | 2025-09-10 | — | — | EP | claimed |
| WO-2022200433-A1 | IMIDAZO[1,2-B]PYRIDAZINE BASED TRICYCLIC COMPOUNDS AS INHIBITORS OF HASPIN AND THERAPEUTIC USES THEREOF | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) | 2022-09-29 | — | — | WO | claimed |
| WO-2022180150-A1 | IMIDAZO[1,2-A]PYRAZINES AS INHIBITORS OF HASPIN AND THERAPEUTIC USES THEREOF | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) | 2022-09-01 | — | — | WO | claimed |
| EP-4045631-A1 | PRODUCTION OF SKELETAL MUSCLE CELLS AND SKELETAL MUSCLE TISSUE FROM PLURIPOTENT STEM CELLS | Georg-August-Universität Göttingen (DE) | 2022-08-24 | — | — | EP | claimed |
| EP-4041308-A1 | MODULATING LYMPHATIC VESSELS IN NEUROLOGICAL DISEASE | University of Virginia Patent Foundation (US) | 2022-08-17 | — | — | EP | claimed |
| WO-2022125392-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING T-CELLS | CHIMERA BIOENGINEERING, INC. (US) | 2022-06-16 | — | — | WO | claimed |
| WO-2022040447-A9 | METHODS FOR TREATING RESPIRATORY DISEASES CHARACTERIZED BY MUCUS HYPERSECRETION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-06-16 | — | — | WO | claimed |
| US-11319363-B2 | Humanized tau antibodies in Alzheimer's disease | AXON NEUROSCIENCE SE (CY) | 2022-05-03 | — | — | US | claimed |
| EP-3969444-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND DISORDERS | The Regents of the University of California (US) | 2022-03-23 | — | — | EP | claimed |
| EP-3970725-A1 | A GAMMA SECRETASE INHIBITOR FOR TREATING HEARING LOSS | Massachusetts Eye & Ear Infirmary (US) | 2022-03-23 | — | — | EP | claimed |
| WO-2022040447-A2 | METHODS FOR TREATING RESPIRATORY DISEASES CHARACTERIZED BY MUCUS HYPERSECRETION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-02-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060960-A1 | GAMMA-SECRETASE INHIBITORS FOR USE IN THE TREATMENT OF INHERITED EPIDERMOLYSIS BULLOSA | BACE1, BACE2, PSENEN | PSEN1 11/4885PSEN2 28/4885APH1B 102/4885 |
| US-20260034099-A1 | CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS | BACE1, BACE2, DSG1 | PSEN1 11/4885PSEN2 16/4885APH1B 89/4885 |
| US-12599587-B2 | Chlorinated tetralin compounds and pharmaceutical compositions | CLIC1, CLCN2, CSNK1D | PSEN1 464/4885PSEN2 447/4885APH1B 3750/4885 |
| US-20260027084-A1 | TREATMENT OF MULTIPLE MYELOMA | BACE1, BACE2, CD47 | PSEN1 150/4885PSEN2 505/4885APH1B 39/4885 |
| US-12559559-B2 | Targeting Galectin-9 as a therapeutic strategy for T-cell exhaustion in T-cell acute lymphoblastic leukemia | LGALS9, LGALS3BP, LGALS1 | PSEN1 2403/4885PSEN2 2764/4885APH1B 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.